Indian Journal of Ophthalmology, 2023 Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers
Debdulal Chakraborty +11 more
doaj +1 more source
Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration. [PDF]
, 2021 The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age-related macular ...
Di Antonio, L. +5 more
core +5 more sources
Biomedicines, 2021 We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included.
Yoshiko Fukuda +6 more
doaj +1 more source
Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy [PDF]
, 2023 Purpose: To evaluate the anatomical and functional outcomes of intravitreal brolucizumab in eyes with chronic central serous chorioretinopathy complicated by pachychoroid neovasculopathy.
Affatato M. +21 more
core +1 more source
Scientific Reports, 2022 In this study we evaluated the effect of intravitreal brolucizumab injections on choroidal thickness in patients with neovascular age-related macular degeneration (nAMD) who previously showed an incomplete response to anti-vascular endothelial growth ...
Ki Woong Bae +2 more
doaj +1 more source
Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration [PDF]
, 2021 PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E)
de Jong, L. A. +5 more
core +1 more source
Effect of Intravitreal Brolucizumab in the Treatment of Polypoidal Choroidal Vasculopathy With Foveal Lipid Exudation. [PDF]
, 2023 A 71-year-old woman with a history of blurred vision in her right eye for nearly two months came to our attention. A complete ophthalmological evaluation, including best-corrected visual acuity measurement, fundus examination, spectral-domain optical ...
Carta V, Lixi F, Peiretti E, Tatti F
core +1 more source
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data [PDF]
, 2020 Aim: To compare the treatment effect of brolucizumab, a novel anti-vascular endothelial growth factor therapeutic, with a putative placebo in patients with wet age-related macular degeneration.
Agostini, H. +8 more
core +1 more source
Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema [PDF]
, 2023 The article presents the characteristics of the first antiangiogenic drug registered for the treatment of diabetic macular edema, ranibizumab, as well as the new long-acting drug ...
Mavlonov N. X.
core +2 more sources
BMC Ophthalmology, 2022 Purpose To report the efficacy and safety of brolucizumab in the treatment of refractory serous pigment epithelial detachment (PED) secondary to polypoidal choroidal vasculopathy (PCV). Methods Twenty-six eyes of 26 patients were included.
Seung Wan Nam +3 more
doaj +1 more source